Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGT001-075 in Uncontrolled Type 2 Diabetes on Metformin
NCT05297045Phase 2Terminated
- Sponsor
- Regor Therapeutics
- Start
- Mar 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RGT-075 in type 2 diabetes mellitus (T2DM), sponsored by Regor Therapeutics. Started Mar 2022; status: terminated.
02
Drugs
RGT-075
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05297045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05297045.